Management of CML-blast crisis

Best Practice and Research: Clinical Haematology

Volumn 29, Issue 3, 2016, Pages 295-307

  Hehlmann, Rüdiger ^a   Saußele, Susanne ^a   Voskanyan, Astghik ^a   Silver, Richard T ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

CML blast crisis; Diagnosis; Early prediction; Prevention; Therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTHRACYCLINE; AXITINIB; AZACITIDINE; BOSUTINIB; CARBOPLATIN; CYTARABINE; DASATINIB; DAUNORUBICIN; DECITABINE; DEXAMETHASONE; ETOPOSIDE; FINGOLIMOD; FLUDARABINE; HOMOHARRINGTONINE; IDARUBICIN; IMATINIB; LONAFARNIB; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NILOTINIB; PONATINIB; PREDNISONE; TIOGUANINE; TRIPTOLIDE; UNINDEXED DRUG; VINCRISTINE; PROTEIN KINASE INHIBITOR;

ALLOTRANSPLANTATION; BLAST CELL CRISIS; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CYTOCHEMISTRY; CYTOGENETICS; FLOW CYTOMETRY; HUMAN; INTENSIVE CARE; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; ALLOGRAFT; BLAST CRISIS; ENZYMOLOGY; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROGNOSIS;

ALLOGRAFTS; BLAST CRISIS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; STEM CELL TRANSPLANTATION;

EID: 84995446611     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2016.10.005     Document Type: Review

References (100)

1. [1] Johansson, B., Fioretos, T., Mitelman, F., Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107 (2002), 76-94.
2. [2] Soverini, S., Hochhaus, A., Nicolini, F.E., et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118 (2011), 1208-1215.
3. [3] Hehlmann, R., How I treat CML blast crisis. Blood 120 (2012), 737-747.
4. [4] Mitelman, F., Levan, G., Nilsson, P.G., et al. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer 18 (1976), 24-30.
5. [5] Alimena, G., De Cuia, M.R., Diverio, D., et al. The karyotype of blastic crisis. Cancer Genet Cytogenet 26 (1987), 39-50.
6. [6] Fabarius, A., Leitner, A., Hochhaus, A., et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118 (2011), 6760-6768.
7. [7] Wang, W., Cortes, J.E., Tang, G., et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 127 (2016), 2742-2750.
8. [8] Chen, Z., Cortes, J.E., Jorgensen, J.L., et al. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia, 2016.
9. [9] Haaß, W., Kleiner, H., Weiß, C., et al. Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 fusion type CML under imatinib therapy. PLoS One, 10, 2015, e0129648.
10. [10] Soverini, S., Martinelli, G., Rosti, G., et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 23 (2005), 4100-4109.
11. [11] Prokocimer, M., Rotter, V., Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84 (1994), 2391-2411.
12. [12] Sill, H., Goldman, J.M., Cross, N.C.P., Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85 (1995), 2013-2016.
13. [13] Grossmann, V., Kohlmann, A., Zenger, M., et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25 (2011), 557-560.
14. [14] Roche-Lestienne, C., Deluche, L., Corm, S., et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL(+) leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111 (2008), 3735-3741.
15. [15] Mullighan, C.G., Miller, C.B., Radtke, I., et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453 (2008), 110-115.
16. [16] Zheng, C., Li, L., Haak, M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 20 (2006), 1028-1034.
17. [17] Radich, J.P., Dai, H., Mao, M., et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103 (2006), 2794-2799.
18. [18] Jamieson, C.H., Ailles, L.E., Dylla, S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004), 657-667.
19. [19] Oehler, V.G., Yeung, K.Y., Choi, Y.E., et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 114 (2009), 3292-3298.
20. [20] Perrotti, D., Jamieson, C., Goldman, J., et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 120 (2010), 2254-2264.
21. [21] Chereda, B., Melo, J.V., Natural course and biology of CML. Ann Hematol 94:Suppl. 2 (2015), 107-121.
22. [22] Skorski, T., Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2 (2002), 351-360.
23. [23] Koptyra, M., Falinski, R., Nowicki, M.O., et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108 (2006), 319-327.
24. [24] Nowicki, M.O., Falinski, R., Koptyra, M., et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104 (2004), 3746-3753.
25. [25] Soverini, S., Gnani, A., Colarossi, S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114 (2009), 2168-2171.
26. [26] Sattler, M., Verma, S., Shrikhande, G., et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 275 (2000), 24273-24278.
27. [27] Marmont, A.M., Damasio, E.E., The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine. Acta Haematol 50 (1973), 1-8.
28. [28] Marks, S.M., Baltimore, D., McCaffrey, R., Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia. N Engl J Med 298 (1978), 812-814.
29. [29] Iacoboni, S.J., Plunkett, W., Kantarjian, H.M., et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 4 (1986), 1079-1088.
30. [30] Deininger, M., O'Brien, S.G., Guilhot, F., et al. International randomized study of interferon vs STI571 (IRIS) 8-Year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annu Meet Abstr, 114, 2009, 1126.
31. [31] Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29 (2011), 1634-1642.
32. [32] Saussele, S., Silver, R.T., Management of chronic myeloid leukemia in blast crisis. Ann Hematol 94:Suppl. 2 (2015), 159-165.
33. [33] Druker, B.J., Sawyers, C.L., Kantarjian, H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344 (2001), 1038-1042.
34. [34] Sawyers, C.L., Hochhaus, A., Feldman, E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99 (2002), 3530-3539.
35. [35] Kantarjian, H.M., Cortes, J., O'Brien, S., et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99 (2002), 3547-3553.
36. [36] Sureda, A., Carrasco, M., de Miguel, M., et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 88 (2003), 1213-1220.
37. [37] Palandri, F., Castagnetti, F., Testoni, N., et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica 93 (2008), 1792-1796.
38. [38] Steegmann, J.L., Baccarani, M., Breccia, M., et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30 (2016), 1648-1671.
39. [39] Talpaz, M., Shah, N.P., Kantarjian, H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006), 2531-2541.
40. [40] Cortes, J., Kim, D.W., Raffoux, E., et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22 (2008), 2176-2183.
41. [41] Saglio, G., Hochhaus, A., Goh, Y.T., et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 116 (2010), 3852-3861.
42. [42] Porkka, K., Koskenvesa, P., Lundan, T., et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112 (2008), 1005-1012.
43. [43] Kantarjian, H., Giles, F., Wunderle, L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354 (2006), 2542-2551.
44. [44] Giles, F.J., Kantarjian, H.M., le Coutre, P.D., et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26 (2012), 959-962.
45. [45] Fruehauf, S., Topaly, J., Buss, E.C., et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109 (2007), 1543-1549.
46. [46] Oki, Y., Kantarjian, H.M., Gharibyan, V., et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109 (2007), 899-906.
47. [47] Quintas-Cardama, A., Kantarjian, H., Garcia-Manero, G., et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. LeukLymphoma 48 (2007), 283-289.
48. [48] Cortes, J., Jabbour, E., Daley, G.Q., et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110 (2007), 1295-1302.
49. [49] Fang, B., Li, N., Song, Y., et al. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol 89 (2010), 1099-1105.
50. [50] Rea, D., Legros, L., Raffoux, E., et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20 (2006), 400-403.
51. [51] Deau, B., Nicolini, F.E., Guilhot, J., et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res 35 (2011), 777-782.
52. [52] Milojkovic, D., Ibrahim, A., Reid, A., et al. Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematol Hematol J 97 (2012), 473-474.
53. [53] Strati, P., Kantarjian, H., Thomas, D., et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120 (2014), 373-380.
54. [54] Ghez, D., Micol, J.B., Pasquier, F., et al. Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. Eur J cancer 2013:49 (1990), 3666-3670 Oxford, England.
55. [55] Doan, V., Wang, A., Prescott, H., Bosutinib for the treatment of chronic myeloid leukemia. Am J Health Syst Pharm 72 (2015), 439-447.
56. [56] Cortes, J.E., Kim, D.W., Pinilla-Ibarz, J., et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369 (2013), 1783-1796.
57. [57] Valent, P., Hadzijusufovic, E., Schernthaner, G.H., et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood 125 (2015), 901-906.
58. [58] Rea, D., Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol 94:Suppl. 2 (2015), 149-158.
59. [59] Gratwohl, A., Brand, R., Apperley, J., et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 91 (2006), 513-521.
60. [60] Saussele, S., Lauseker, M., Gratwohl, A., et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115 (2010), 1880-1885.
61. [61] Saussele, S., Lauseker, M., Muller, M.C., et al. Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: update on the survival outcome following allogeneic HSCT after imatinib failure; results of the German CML study IV. Blood, 124, 2014 Abstract No. 2567.
62. [62] Jiang, H., Xu, L.P., Liu, D.H., et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transpl 49 (2014), 1146-1154.
63. [63] Gratwohl, A., Pfirrmann, M., Zander, A., et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. Leukemia 30 (2016), 562-569.
64. [64] Oyekunle, A., Zander, A.R., Binder, M., et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol 92 (2013), 487-496.
65. [65] Gratwohl, A., Heim, D., Current role of stem cell transplantation in chronic myeloid leukaemia. Best Pract Res Clin Haematol 22 (2009), 431-443.
66. [66] Jabbour, E., Kantarjian, H., O'Brien, S., et al. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood 107 (2006), 480-482.
67. [67] Gratwohl, A., Baldomero, H., Passweg, J., The role of hematopoietic stem cell transplantation in chronic myeloid leukemia. Ann Hematol 94:Suppl. 2 (2015), 177-186.
68. [68] Neviani, P., Santhanam, R., Trotta, R., et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8 (2005), 355-368.
69. [69] Lucas, C.M., Harris, R.J., Giannoudis, A., et al. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117 (2011), 6660-6668.
70. [70] Lucas, C.M., Milani, M., Butterworth, M., et al. High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia. Leukemia 30 (2016), 1273-1281.
71. [71] Hurtz, C., Hatzi, K., Cerchietti, L., et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208 (2011), 2163-2174.
72. [72] Zhang, H., Li, H., Xi, H.S., et al. HIF1α is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 119 (2012), 2595-2607.
73. [73] Zhao, C., Chen, A., Jamieson, C.H., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature, 458, 2009 776-U117.
74. [74] Mak, D.H., Wang, R.Y., Schober, W.D., et al. Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 26 (2012), 788-794.
75. [75] Pellicano, F., Simara, P., Sinclair, A., et al. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 25 (2011), 1159-1167.
76. [76] Xie, J., Zhang, X., Fang, B.Z., et al. Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;). Chin Med Sci J 28 (2013), 127-128.
77. [77] Pemovska, T., Johnson, E., Kontro, M., et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519 (2015), 102-105.
78. [78] Pietarinen, P.O., Pemovska, T., Kontro, M., et al. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. Blood Cancer J, 5, 2015, e309.
79. [79] Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006-2017.
80. [80] Kaeda, J., O'Shea, D., Szydlo, R.M., et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood 107 (2006), 4171-4176.
81. [81] Hehlmann, R., Müller, M.C., Lauseker, M., et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32 (2014), 415-423.
82. [82] Mahon, F.X., Discontinuation of tyrosine kinase therapy in CML. Ann Hematol 94:Suppl. 2 (2015), S187-S193.
83. [83] Hasford, J., Baccarani, M., Hoffmann, V., et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118 (2011), 686-692.
84. [84] Pfirrmann, M., Baccarani, M., Saussele, S., et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30 (2016), 48-56.
85. [85] Verma, D., Kantarjian, H.M., Jones, D., et al. Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood 114 (2009), 2232-2235.
86. [86] Schoch, C., Haferlach, T., Kern, W., et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 17 (2003), 461-463.
87. [87] Cortes, J.E., Talpaz, M., Giles, F., et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101 (2003), 3794-3800.
88. [88] Voskanyan, A., Dietz, C.T., Fabarius, A.C., et al. Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 2016 Abstract P201.
89. [89] Haferlach, C., Bacher, U., Schnittger, S., et al. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia 24 (2010), 638-640.
90. [90] Verma, D., Kantarjian, H., Shan, J., et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116 (2010), 2673-2681.
91. [91] Baccarani, M., Deininger, M.W., Rosti, G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013:122 (2013), 872-884.
92. [92] Hanfstein, B., Muller, M.C., Hochhaus, A., Response-related predictors of survival in CML. Ann Hematol 94:Suppl. 2 (2015), 227-239.
93. [93] Hanfstein, B., Shlyakhto, V., Lauseker, M., et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28 (2014), 1988-1992.
94. [94] Branford, S., Yeung, D.T., Parker, W.T., et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124 (2014), 511-518.
95. [95] Neviani, P., Santhanam, R., Oaks, J.J., et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117 (2007), 2408-2421.
96. [96] Agarwal, A., MacKenzie, R., Oddo, J., et al. A novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCR-ABLT315I mutant, and demonstrates enhanced efficacy in combination with ABL tyrosine kinase inhibitors. Blood, 118, 2011, 1603 Abstract 3757.
97. [97] Shah, N.P., Cortes, J.E., Martinelli, G., et al. Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323. Blood ASH Annu Meet Abstr, 124, 2014, 4539.
98. [98] Court Recart, A.C., Sadarangani, A., Goff, D., et al. Combination targeted therapy to impair self-renewal capacity of human blast crisis leukemia stem cells. Blood, 118, 2011, 737 Abstract 1693.
99. [99] Gallipoli, P., Cook, A., Rhodes, S., et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood 124 (2014), 1492-1501.
100. [100] Wang, W., Lv, F.F., Du, Y., et al. The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis. Cancer Cell Int, 15, 2015, 10.